Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models
Fumiyuki Sasaki, Tomoaki Koga, Mai Ohba, Kazuko Saeki, Toshiaki Okuno, Keijiro Ishikawa, Takahito Nakama, Shintaro Nakao, Shigeo Yoshida, Tatsuro Ishibashi, Hamid Ahmadieh, Mozhgan Rezaei Kanavi, Ali Hafezi-Moghadam, Josef M. Penninger, Koh-Hei Sonoda, Takehiko Yokomizo
Fumiyuki Sasaki, Tomoaki Koga, Mai Ohba, Kazuko Saeki, Toshiaki Okuno, Keijiro Ishikawa, Takahito Nakama, Shintaro Nakao, Shigeo Yoshida, Tatsuro Ishibashi, Hamid Ahmadieh, Mozhgan Rezaei Kanavi, Ali Hafezi-Moghadam, Josef M. Penninger, Koh-Hei Sonoda, Takehiko Yokomizo
View: Text | PDF
Research Article Angiogenesis Inflammation

Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models

  • Text
  • PDF
Abstract

Age-related macular degeneration (AMD), a progressive chronic disease of the central retina, is associated with aging and is a leading cause of blindness worldwide. Here, we demonstrate that leukotriene B4 (LTB4) receptor 1 (BLT1) promotes laser-induced choroidal neovascularization (CNV) in a mouse model for wet-type AMD. CNV was significantly less in BLT1-deficient (BLT1-KO) mice compared with BLT1-WT controls. Expression of several proangiogenic and profibrotic factors was lower in BLT1-KO eyes than in BLT1-WT eyes. LTB4 production in the eyes was substantially increased in the early phase after laser injury. BLT1 was highly expressed in M2 macrophages in vitro and in vivo, and ocular BLT1+ M2 macrophages were increased in the aged eyes after laser injury. Furthermore, M2 macrophages were rapidly attracted by LTB4 and subsequently produced VEGF-A– through BLT1-mediated signaling. Consequently, intravitreal injection of M2 macrophages augmented CNV formation, which was attenuated by BLT1 deficiency. Thus, laser-induced injury to the retina triggered LTB4 production and attracted M2 macrophages via BLT1, leading to development of CNV. A selective BLT1 antagonist (CP105696) and 3 LTB4 inhibitors (zileuton, MK-886, and bestatin) reduced CNV in a dose-dependent manner. CP105696 also inhibited the accumulation of BLT1+ M2 macrophages in the laser-injured eyes of aged mice. Together, these results indicate that the LTB4-BLT1 axis is a potentially novel therapeutic target for CNV of wet-type AMD.

Authors

Fumiyuki Sasaki, Tomoaki Koga, Mai Ohba, Kazuko Saeki, Toshiaki Okuno, Keijiro Ishikawa, Takahito Nakama, Shintaro Nakao, Shigeo Yoshida, Tatsuro Ishibashi, Hamid Ahmadieh, Mozhgan Rezaei Kanavi, Ali Hafezi-Moghadam, Josef M. Penninger, Koh-Hei Sonoda, Takehiko Yokomizo

×

Figure 9

The effects of a BLT1 antagonist and LTB4 synthesis inhibitors on development of CNV.

Options: View larger image (or click on image) Download as PowerPoint
The effects of a BLT1 antagonist and LTB4 synthesis inhibitors on develo...
Images of iB4 staining (A) and CNV volume (B) in the RPE-choroid from aged WT mice (>20 weeks old) after administration of 0.2–20 pmol of CP105696 (a BLT1 antagonist; filled circles) or 20 pmol of zileuton (a 5-LO inhibitor), MK-886 (a FLAP inhibitor), or bestatin (a LTA4H inhibitor) (filled triangles), or vehicle (open circles). n = 4–9 mice per group. (C and D) Images of H&E staining (C) and CNV lesion area (D). H&E staining of the retinas after aged WT mice (>20 weeks old) with laser-induced injury were treated with CP105696, zileuton, MK-886, and bestatin (20 pmol/eye) or DMSO. Yellow dotted lines show the lesion area. n = 3-6 per group. (E and F) The number of the ocular-infiltrating CD206+ or CD206+BLT1+ M2 macrophages was analyzed on day 3 after laser injury from CP105696- (20 pmol/eye) or DMSO-injected WT mice (> 20 weeks old). n = 3–4 per group. Scale bar: 100 μm (A and C). *P < 0.05; **P < 0.01 (1-way ANOVA with Dunnett’s post hoc test [B and D] and Student’s t test [E and F]). Results are representative of at least 2 independent experiments (A–D).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts